Guselkumab

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.

The VISIBLE trial demonstrated that intentional efforts to recruit and retain patients with skin of color result in a speedy enrollment process and diverse patient pool, according to a study.

PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio.

Ethan Craig, MD, spoke with Healio about treatment options currently available in psoriatic arthritis.

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.

Guselkumab can effectively and safely treat patients with psoriasis for up to 2 years, according to a study.

In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a study published in JAMA Dermatology.

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.